Get the Daily Brief
Latest Biotech News
AI and Machine Learning Propel Innovations in Drug Discovery and Bioprocessing
Advancements in AI are accelerating biotechnology, exemplified by Jura Bio's VISTA platform for large-scale de novo antibody design using AI-driven data loops combined with experimental...
Neuroscience Insights: Gut-Brain Communication and Neurovascular Imaging
Recent studies deepen understanding of neurobiological processes. Duke University researchers identified a gut-brain communication mechanism where colonic neuropods detect bacterial flagellin...
Leadership Changes and Corporate Reshaping in Biotech Sector
Several biopharma and med-tech firms announced significant leadership appointments, restructurings, and workforce adjustments. Korro Bio, despite cutting 20% of staff, reaffirmed its clinical...
Novel Genetic Approaches to Disease Control and Biodiversity Conservation
Innovations in gene editing offer transformative potential across health and environment. An international team used CRISPR to introduce a naturally occurring allele into Anopheles stephensi...
Thermo Fisher Raises 2025 Outlook After Strong Q2 Results
Thermo Fisher Scientific reported better-than-expected Q2 earnings, with revenues up 3% year-over-year to $10.86 billion, driven by growth in life sciences and biopharma services. The company...
Sanofi Acquires Vicebio to Expand Respiratory Vaccine Portfolio
French pharma Sanofi agreed to acquire UK-based vaccine firm Vicebio for $1.15 billion upfront, with potential milestone payments of $450 million. Vicebio’s lead candidate, VXB-241, is a bivalent...
FDA Rejects Replimune’s Oncolytic Virus Therapy for Melanoma
The FDA issued a complete response letter rejecting Replimune’s RP1 oncolytic virus therapy for advanced melanoma. The agency cited inadequate and uncontrolled clinical investigation and concerns...
Abivax’s Ulcerative Colitis Drug Shows Positive Phase 3 Data, Shares Soar
French biotech Abivax announced positive phase 3 results for obefazimod, its orally available miRNA-124 enhancer for ulcerative colitis, achieving a 16.4% placebo-adjusted clinical remission at...
Dispatch Bio Launches with $216M to Target Solid Tumors Using Novel Immunotherapy
Dispatch Bio debuted its platform delivering a viral vector carrying a universal antigen called Flare that tags solid tumor cells, enabling immune system recognition and clearance without damaging...
CRISPR Edit in Mosquito Gene FREP1 Blocks Malaria Transmission
Researchers at UC San Diego and Johns Hopkins used CRISPR-Cas9 to introduce a naturally occurring variant in the mosquito FREP1 gene that makes mosquitoes refractory to malaria infection. This...
Long-Read Sequencing Enhances Human Genome Structural Variant Maps
Two international research teams applied long-read sequencing to over 1,000 genomes from diverse populations, providing unprecedented detail on structural variants (SVs) including insertions,...
Advancements in Biomanufacturing: Media Optimization and Inline Buffer Preparation
Researchers at Johns Hopkins developed a hybrid machine-learning and thermodynamic modeling system to optimize cell culture media formulations for biotherapeutic production, enhancing data...
Autoantibodies Influence Cancer Immunotherapy Response, Reveals Yale Study
A landmark study by Yale and Fred Hutchinson Cancer Center found that naturally occurring autoantibodies can strongly affect patient responses to checkpoint immunotherapy. Certain autoantibodies...
Sanofi’s $1.15 Billion Bet on Non-mRNA Respiratory Vaccines
Sanofi announced a $1.15 billion upfront acquisition of Vicebio, a London-based biotech developing combination vaccines targeting respiratory syncytial virus (RSV) and human metapneumovirus...
Sarepta Halts Duchenne Therapy Shipments Amid FDA Safety Concerns
Sarepta Therapeutics has reversed its prior stance and agreed to voluntarily pause shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy (DMD), following FDA requests tied to...
Thermo Fisher Rises on Q2 Beat and Raised 2025 Outlook
Thermo Fisher Scientific reported Q2 2025 revenue of $10.86 billion, beating analyst estimates, driven by a 6% rise in life sciences solutions. Adjusted earnings per share were $5.36, surpassing...
Abivax’s Obefazimod Shows Promise in Phase 3 Ulcerative Colitis Trials
French biotech Abivax announced positive Phase 3 results for obefazimod, an oral miRNA-124 enhancer for moderate-to-severe ulcerative colitis, showing a 16.4% placebo-adjusted clinical remission...
Dispatch Bio Launches with $216 Million for Universal Solid Tumor Immunotherapy
Dispatch Bio debuted as a new biotech utilizing a viral vector platform named Flare to tag solid tumor cells with a universal antigen, promoting immune clearance without harming healthy tissue....
Long-Read Sequencing Enhances Human Genome Structural Variant Detection
Two international research groups employed Oxford Nanopore long-read sequencing to analyze more than 1,000 genomes from the 1000 Genomes Project, detecting novel structural variants (SVs)...
Genetic CRISPR Edit Blocks Malaria Transmission in Mosquitoes
A research team from UCSD and Johns Hopkins engineered Anopheles stephensi mosquitoes using CRISPR-Cas9 to introduce a naturally occurring FREP1 gene variant that prevents Plasmodium parasite...